Robert Malenka Sells 11,264 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 11,264 shares of Maplight Therapeutics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $18.42, for a total transaction of $207,482.88. Following the completion of the sale, the director owned 325,795 shares in the company, valued at approximately $6,001,143.90. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Maplight Therapeutics Stock Down 1.5%

MPLT stock traded down $0.28 during mid-day trading on Tuesday, hitting $18.02. The company had a trading volume of 97,940 shares, compared to its average volume of 185,529. The firm’s 50-day moving average price is $17.83. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $21.55. The company has a market capitalization of $817.57 million and a P/E ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MPLT. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. Wall Street Zen raised shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Morgan Stanley began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 target price on the stock. Finally, Leerink Partners began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Institutional Trading of Maplight Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MPLT. T. Rowe Price Investment Management Inc. bought a new stake in Maplight Therapeutics in the fourth quarter worth about $49,168,000. Invesco Ltd. purchased a new stake in shares of Maplight Therapeutics in the fourth quarter worth approximately $228,000. Vestal Point Capital LP bought a new stake in shares of Maplight Therapeutics during the 4th quarter worth approximately $6,763,000. Tudor Investment Corp ET AL bought a new stake in shares of Maplight Therapeutics during the 4th quarter worth approximately $840,000. Finally, Orbimed Advisors LLC purchased a new position in Maplight Therapeutics during the 4th quarter valued at $952,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.